495 related articles for article (PubMed ID: 20687209)
1. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.
Vandenberghe R; Van Laere K; Ivanoiu A; Salmon E; Bastin C; Triau E; Hasselbalch S; Law I; Andersen A; Korner A; Minthon L; Garraux G; Nelissen N; Bormans G; Buckley C; Owenius R; Thurfjell L; Farrar G; Brooks DJ
Ann Neurol; 2010 Sep; 68(3):319-29. PubMed ID: 20687209
[TBL] [Abstract][Full Text] [Related]
2. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
[TBL] [Abstract][Full Text] [Related]
3. Brain uptake and safety of Flutemetamol F 18 injection in Japanese subjects with probable Alzheimer's disease, subjects with amnestic mild cognitive impairment and healthy volunteers.
Miki T; Shimada H; Kim JS; Yamamoto Y; Sugino M; Kowa H; Heurling K; Zanette M; Sherwin PF; Senda M
Ann Nucl Med; 2017 Apr; 31(3):260-272. PubMed ID: 28181118
[TBL] [Abstract][Full Text] [Related]
4. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads.
Thurfjell L; Lilja J; Lundqvist R; Buckley C; Smith A; Vandenberghe R; Sherwin P
J Nucl Med; 2014 Oct; 55(10):1623-8. PubMed ID: 25146124
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.
Nelissen N; Van Laere K; Thurfjell L; Owenius R; Vandenbulcke M; Koole M; Bormans G; Brooks DJ; Vandenberghe R
J Nucl Med; 2009 Aug; 50(8):1251-9. PubMed ID: 19617318
[TBL] [Abstract][Full Text] [Related]
6. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease.
Hatashita S; Yamasaki H; Suzuki Y; Tanaka K; Wakebe D; Hayakawa H
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):290-300. PubMed ID: 24085503
[TBL] [Abstract][Full Text] [Related]
7. Comparison of
Zeydan B; Schwarz CG; Przybelski SA; Lesnick TG; Kremers WK; Senjem ML; Kantarci OH; Min PH; Kemp BJ; Jack CR; Kantarci K; Lowe VJ
J Nucl Med; 2022 Aug; 63(8):1239-1244. PubMed ID: 34916245
[TBL] [Abstract][Full Text] [Related]
8. Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data.
Lundqvist R; Lilja J; Thomas BA; Lötjönen J; Villemagne VL; Rowe CC; Thurfjell L
J Nucl Med; 2013 Aug; 54(8):1472-8. PubMed ID: 23740104
[TBL] [Abstract][Full Text] [Related]
9. Combination of biomarkers: PET [18F]flutemetamol imaging and structural MRI in dementia and mild cognitive impairment.
Thurfjell L; Lötjönen J; Lundqvist R; Koikkalainen J; Soininen H; Waldemar G; Brooks DJ; Vandenberghe R
Neurodegener Dis; 2012; 10(1-4):246-9. PubMed ID: 22301718
[TBL] [Abstract][Full Text] [Related]
10. Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients.
Byun BH; Kim BI; Park SY; Ko IO; Lee KC; Kim KM; Kim YK; Lee JY; Bu SH; Kim JH; Chi DY; Ha JH; Lim SM
Medicine (Baltimore); 2017 Mar; 96(12):e6441. PubMed ID: 28328855
[TBL] [Abstract][Full Text] [Related]
11. Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.
Wolk DA; Sadowsky C; Safirstein B; Rinne JO; Duara R; Perry R; Agronin M; Gamez J; Shi J; Ivanoiu A; Minthon L; Walker Z; Hasselbalch S; Holmes C; Sabbagh M; Albert M; Fleisher A; Loughlin P; Triau E; Frey K; Høgh P; Bozoki A; Bullock R; Salmon E; Farrar G; Buckley CJ; Zanette M; Sherwin PF; Cherubini A; Inglis F
JAMA Neurol; 2018 Sep; 75(9):1114-1123. PubMed ID: 29799984
[TBL] [Abstract][Full Text] [Related]
12. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
[TBL] [Abstract][Full Text] [Related]
13. Amyloid imaging in cognitively normal older adults: comparison between (18)F-flutemetamol and (11)C-Pittsburgh compound B.
Adamczuk K; Schaeverbeke J; Nelissen N; Neyens V; Vandenbulcke M; Goffin K; Lilja J; Hilven K; Dupont P; Van Laere K; Vandenberghe R
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):142-151. PubMed ID: 26260650
[TBL] [Abstract][Full Text] [Related]
14. An exploratory efficacy study of the amyloid imaging agent [(18)F]flutemetamol in Japanese Subjects.
Senda M; Yamamoto Y; Sasaki M; Yamane T; Brooks DJ; Farrar G; McParland B; Heurling K
Ann Nucl Med; 2015 Jun; 29(5):391-9. PubMed ID: 25874747
[TBL] [Abstract][Full Text] [Related]
15. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.
Kemppainen NM; Aalto S; Wilson IA; Någren K; Helin S; Brück A; Oikonen V; Kailajärvi M; Scheinin M; Viitanen M; Parkkola R; Rinne JO
Neurology; 2007 May; 68(19):1603-6. PubMed ID: 17485647
[TBL] [Abstract][Full Text] [Related]
16. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies.
Rinne JO; Wong DF; Wolk DA; Leinonen V; Arnold SE; Buckley C; Smith A; McLain R; Sherwin PF; Farrar G; Kailajärvi M; Grachev ID
Acta Neuropathol; 2012 Dec; 124(6):833-45. PubMed ID: 23053137
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.
Vallabhajosula S
Semin Nucl Med; 2011 Jul; 41(4):283-99. PubMed ID: 21624562
[TBL] [Abstract][Full Text] [Related]
18. Amyloid imaging with (11)C-PIB PET/CT and glucose metabolism with (18)F-FDG PET/CT in a study on cognitive impairment in the clinical setting.
Banzo I; Jiménez-Bonilla J; Ortega-Nava F; Quirce R; Martínez-Rodríguez I; de Arcocha-Torres M; Rodríguez E; Vázquez JL; Sánchez PJ; Martínez-Amador N; Ibañez-Bravo S; Carril JM
Nucl Med Commun; 2014 Mar; 35(3):238-44. PubMed ID: 24240196
[TBL] [Abstract][Full Text] [Related]
19. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration.
Rabinovici GD; Furst AJ; O'Neil JP; Racine CA; Mormino EC; Baker SL; Chetty S; Patel P; Pagliaro TA; Klunk WE; Mathis CA; Rosen HJ; Miller BL; Jagust WJ
Neurology; 2007 Apr; 68(15):1205-12. PubMed ID: 17420404
[TBL] [Abstract][Full Text] [Related]
20. Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis.
Heurling K; Leuzy A; Zimmer ER; Lubberink M; Nordberg A
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):362-373. PubMed ID: 26440450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
